Finerenone
Finerenone is a non-steroidal mineralocorticoid receptor antagonist used to lower the risk of kidney and heart problems in adults with chronic kidney disease linked to type 2 diabetes, and in adults with heart failure with an ejection fraction of 40% or higher.
🧬 Where this information comes from Click to expand
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 1 clinical label set within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
Kerendia (finerenone), on the U.S. market since about 2021, blocks the receptor that aldosterone switches on, calming scarring and inflammation in the kidneys and heart. It is usually added alongside other kidney and heart medicines to lower kidney and heart risks in adults with chronic kidney disease from type 2 diabetes, and in adults with heart failure with an ejection fraction (pumping strength) of 40% or higher. Most people feel little from it day to day, though some notice dizziness or lightheadedness from lower blood pressure. The thing to watch is high potassium, which is often silent, so the blood tests before starting, at about 4 weeks and periodically after really matter.
Clinical pearls
- Avoid grapefruit and grapefruit juice, which raise finerenone levels and, with them, the risk of high potassium.
- Erythromycin, verapamil, amiodarone, rifampicin and efavirenz all change finerenone levels, so every prescriber needs to know you take it.
- Potassium supplements and potassium-based salt substitutes add to the same risk and call for more frequent potassium checks.
- A small rise in creatinine (a kidney blood test) can appear soon after starting, which is why eGFR is rechecked.
Patient information guide A plain-language walkthrough of Finerenone, written from its FDA label.
What Finerenone is used for
▾
Finerenone, sold as Kerendia, is approved for these uses in adults:
- Kerendia lowers the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, non-fatal heart attack and hospitalization for heart failure in chronic kidney disease (CKD) associated with type 2 diabetes.
- Kerendia lowers the risk of cardiovascular death, hospitalization for heart failure and urgent heart failure visits in heart failure with LVEF of 40% or higher.
How Finerenone works
▾
Finerenone is a non-steroidal, selective blocker of the mineralocorticoid receptor (MR). Aldosterone and cortisol activate this receptor, which affects sodium reabsorption and gene activity in the kidneys, heart and blood vessels.
Overactivation of this receptor is thought to contribute to fibrosis (scarring) and inflammation. Finerenone binds strongly to the MR and does not meaningfully affect androgen, progesterone, estrogen or glucocorticoid receptors.
Finerenone dosage
▾
Kerendia tablets are taken by mouth once daily, with or without food. The starting dose depends on your eGFR, and your potassium must be checked first. The dose may be raised after 4 weeks, lowered, or paused depending on your potassium and kidney tests.
- If you can't swallow tablets whole, they can be crushed and mixed with water or soft food like applesauce just before taking.
- If you miss a dose, take it as soon as you remember that same day. If not, skip it and take the next dose as scheduled.
Follow your prescriber's instructions and the label.
Dosing details from the FDA-approved label
From the Finerenone prescribing information (“Dosage and Administration”). Doses are set by your prescriber for your product, condition, kidney function and age — never change a dose on your own.
- CKD associated with T2DM, starting dose with eGFR ≥ 60 mL/min/1.73m2
- 20 mg orally once daily
- Target daily dose is 20 mg orally
- Measure serum potassium 4 weeks after initiating treatment and adjust dose per Table 2
- Do not initiate if serum potassium is > 5.0 mEq/L; measure serum potassium and eGFR before initiation
- CKD associated with T2DM, starting dose with eGFR ≥ 25 to < 60 mL/min/1.73m2
- 10 mg orally once daily
- Increase to 20 mg once daily after 4 weeks if serum potassium ≤ 4.8 mEq/L (if eGFR has decreased by more than 30% compared to previous measurement, maintain 10 mg dose)
- Initiation is not recommended if eGFR < 25 mL/min/1.73m2
- Heart failure with LVEF ≥ 40%, eGFR at initiation ≥ 60 mL/min/1.73m2
- Start 20 mg orally once daily
- Target daily dose is 40 mg orally once daily
- Adjust dose per Table 3 based on serum potassium and eGFR measured 4 weeks after initiation
- Target dose depends on eGFR at initiation; withhold if serum potassium ≥ 5.5 mEq/L per Table 3
- Heart failure with LVEF ≥ 40%, eGFR at initiation ≥ 25 to < 60 mL/min/1.73m2
- Start 10 mg orally once daily
- Target daily dose is 20 mg orally once daily
- Adjust dose per Table 3 based on serum potassium and eGFR measured 4 weeks after initiation
- Maintain 20 mg once daily if eGFR < 60 mL/min/1.73m2 at initiation
- Patients unable to swallow whole tablets
- Tablet may be crushed and mixed with water or soft foods such as applesauce immediately prior to use and administered orally
- Tablets may be taken with or without food
- Missed dose
- Take a missed dose as soon as possible after it is noticed, but only on the same day
- Otherwise skip the dose and continue with the next dose as prescribed
Read the label’s full dosing text
2 DOSAGE AND ADMINISTRATION The recommended starting dosage is 10 mg or 20 mg orally once daily based on eGFR and serum potassium thresholds. ( 2.1 ) Increase dosage after 4 weeks to the target dose of 20 mg once daily for CKD and T2DM based on eGFR and serum potassium thresholds. ( 2.3 ) Increase dosage after 4 weeks to the target dose of 20 mg or 40 mg once daily for HF with LVEF ≥ 40% based on eGFR and serum potassium thresholds. ( 2.3 ) Tablets may be taken with or without food ( 2.2 ) 2.1 Prior to Initiation of Kerendia Measure serum potassium levels and eGFR before initiation. Do not initiate treatment if serum potassium is > 5.0 mEq/L [see Warnings and Precautions (5.1) ]. 2.2 Recommended Starting Dosage The recommended starting dose of Kerendia is based on eGFR and is presented in Table 1. Table 1: Recommended Starting Dosage eGFR (mL/min/1.73m 2 ) Starting Dose ≥ 60 20 mg orally once daily ≥ 25 to < 60 10 mg orally once daily < 25 Initiation is not recommended For patients who are unable to swallow whole tablets, Kerendia may be crushed and mixed with water or soft foods such as applesauce immediately prior to use and administered orally [see Clinical Pharmacology (12.3) ] . 2.3 Monitoring and Dosage Adjustment CKD associated with T2DM The target daily dose of Kerendia is 20 mg orally. Measure serum potassium 4 weeks after initiating treatment and adjust dose (see Table 2 ); if serum potassium levels are > 4.8 to 5.0 mEq/L, initiation of Kerendia treatment may be considered with additional serum potassium monitoring within the first 4 weeks based on clinical judgment and serum potassium levels [see Warnings and Precautions (5.1) ]. Measure serum potassium 4 weeks after a dose adjustment and periodically throughout treatment, and adjust the dose as needed (see Table 2 ) [see Warnings and Precautions (5.1) and Drug Interactions (7.1) ]. Table 2: Dose Adjustment Based on Current Serum Potassium Concentration and Current Dose (CKD associated with T2DM) Current Kerendia Dose 10 mg once daily 20 mg once daily Current Serum Potassium (mEq/L) ≤ 4.8 Increase the dose to 20 mg once daily. If eGFR has decreased by more than 30% compared to previous measurement, maintain 10 mg dose. Maintain 20 mg once daily. > 4.8 – 5.5 Maintain 10 mg once daily. Maintain 20 mg once daily. > 5.5 Withhold Kerendia.
Excerpted — the section continues on the label. Read the full Dosage and Administration section on DailyMed →
Finerenone side effects
▾
The most common side effects in studies were:
Common side effects
- High potassium (hyperkalemia)
- Low blood pressure (hypotension)
- Low sodium (hyponatremia)
- Worsening kidney function (seen more often in heart failure)
- Lower eGFR on blood tests
- In heart failure, kidney-related problems such as reduced kidney function, lower eGFR and acute kidney injury
When to get medical help
- Call your doctor if you have signs of high potassium or if your blood tests show high potassium. High potassium is the most important risk and can lead to hospitalization.
- Tell your doctor right away if your kidney function worsens. This has been reported in people with heart failure, and rarely it has been severe enough to need hospitalization.
- Seek medical help if you take too much. The most likely effect of an overdose is high potassium.
- Get help if you have signs of an allergic reaction to any ingredient in Kerendia.
Finerenone warnings and precautions
▾
- High potassium: risk rises with lower kidney function, higher starting potassium, and potassium-raising medicines or supplements. Do not start if potassium is above 5.0 mEq/L.
- Worsening kidney function in heart failure: rarely severe. eGFR is measured before starting and when the dose changes.
- Early creatinine rise: starting Kerendia may cause a small initial increase in blood creatinine.
- Severe liver impairment: avoid use.
Finerenone interactions
▾
Because finerenone is broken down mainly by the CYP3A4 liver enzyme, many drug interactions involve that enzyme.
- Strong CYP3A4 inhibitors: contraindicated, since they raise finerenone levels.
- Grapefruit and grapefruit juice: avoid, for the same reason.
- Moderate or weak CYP3A4 inhibitors (erythromycin, verapamil, amiodarone): raise levels, so potassium is monitored and the dose may change.
- Strong or moderate CYP3A4 inducers (rifampicin, efavirenz): lower levels and may reduce effectiveness. Avoid.
- Potassium-raising drugs or supplements: need more frequent potassium checks.
- CYP2C8 drugs at the 40 mg dose: levels can rise, so closer monitoring is needed.
Interactions listed in the FDA-approved label
From the Finerenone prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.
- Strong CYP3A4 inhibitors: Increase finerenone exposure, which may increase the risk of Kerendia adverse reactions. Concomitant use is contraindicated.
- Grapefruit or grapefruit juice: Listed with CYP3A4 inhibitor interactions; the label advises against intake. Avoid concomitant intake.
- Moderate or weak CYP3A4 inhibitors: Increase finerenone exposure, which may increase the risk of Kerendia adverse reactions. Monitor serum potassium during drug initiation or dosage adjustment of either Kerendia or the inhibitor, and adjust Kerendia dosage as appropriate.
- Strong or moderate CYP3A4 inducers: Decrease finerenone exposure, which may reduce the efficacy of Kerendia. Avoid concomitant use.
- Sensitive CYP2C8 substrates: Kerendia is a weak CYP2C8 inhibitor at 40 mg and increases exposure of CYP2C8 substrates, which may increase the risk of adverse reactions related to these substrates. Monitor patients more frequently for adverse reactions if Kerendia 40 mg is co-administered.
- Drugs or supplements that increase serum potassium: Concomitant therapy may increase serum potassium. More frequent serum potassium monitoring is warranted.
Read the label’s full interactions text
7 DRUG INTERACTIONS Strong CYP3A4 Inhibitors: Use is contraindicated. ( 7.1 ) Grapefruit or grapefruit juice: Avoid concomitant use. ( 7.1 ) Moderate or weak CYP3A4 Inhibitors: Monitor serum potassium during drug initiation or dosage adjustment of either Kerendia or the moderate or weak CYP3A4 inhibitor, and adjust Kerendia dosage as appropriate ( 7.1 ) Strong or moderate CYP3A4 Inducers: Avoid concomitant use. ( 7.1 ) Sensitive CYP2C8 substrates at Kerendia 40 mg: Monitor more frequently for adverse reactions. ( 7.2 ) 7.1 Effect of Other Drugs on Kerendia Strong CYP3A4 Inhibitors Kerendia is a CYP3A4 substrate. Concomitant use with a strong CYP3A4 inhibitor increases finerenone exposure [see Clinical Pharmacology (12.3) ] , which may increase the risk of Kerendia adverse reactions. Concomitant use of Kerendia with strong CYP3A4 inhibitors is contraindicated [see Contraindications (4) ] . Avoid concomitant intake of grapefruit or grapefruit juice. Moderate and Weak CYP3A4 Inhibitors Kerendia is a CYP3A4 substrate. Concomitant use with a moderate or weak CYP3A4 inhibitor increases finerenone exposure [see Clinical Pharmacology (12.3) ] , which may increase the risk of Kerendia adverse reactions. Monitor serum potassium during drug initiation or dosage adjustment of either Kerendia or the moderate or weak CYP3A4 inhibitor, and adjust Kerendia dosage as appropriate [see Dosing and Administration (2.3) and Drug Interaction (7.2) ] . Strong and Moderate CYP3A4 Inducers Kerendia is a CYP3A4 substrate. Concomitant use of Kerendia with a strong or moderate CYP3A4 inducer decreases finerenone exposure [see Clinical Pharmacology (12.3) ], which may reduce the efficacy of Kerendia. Avoid concomitant use of Kerendia with strong or moderate CYP3A4 inducers. 7.2 Effect of Kerendia on Other Drugs CYP2C8 Substrates Kerendia is a weak CYP2C8 inhibitor at 40 mg.
Excerpted — the section continues on the label. Read the full Drug Interactions section on DailyMed →
Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.
Before taking Finerenone
▾
- Do not use with adrenal insufficiency, a known allergy to Kerendia, or strong CYP3A4 inhibitors.
- Potassium above 5.0 mEq/L means treatment should not be started.
- Starting is not recommended with eGFR below 25.
- Avoid in severe liver impairment. Moderate impairment may need extra potassium monitoring.
- No human pregnancy data exist, and animal studies showed developmental toxicity.
- Avoid breastfeeding during treatment and for 1 day after.
- Not established for people under 18.
- No dose change is needed for older adults.
Finerenone overdose
▾
If you suspect an overdose, stop Kerendia right away and get medical help. The most likely effect is high potassium, which is treated with standard measures. Dialysis is unlikely to remove finerenone effectively because it binds strongly to proteins in the blood.
What Finerenone does in the body
▾
In studies of CKD with type 2 diabetes, finerenone lowered urine albumin-to-creatinine ratio (a marker of kidney damage) by about 31 to 32% compared with placebo at Month 4, and the effect lasted. It lowered average systolic blood pressure by about 3 mmHg and diastolic by 1 to 2 mmHg. At twice the maximum recommended dose it did not meaningfully lengthen the QT interval, a heart rhythm measure.
How your body processes Finerenone
▾
Finerenone is fully absorbed after you swallow it, but part is broken down on the first pass through the body, so about 44% reaches the bloodstream. Peak levels come within about 0.5 to 1.25 hours, and high-fat food does not meaningfully change exposure. The half-life is about 2 to 3 hours, and steady state is reached after 2 days. It is mainly broken down by CYP3A4 and to a lesser extent CYP2C8 into inactive products, and about 80% is excreted in urine.
How to store Finerenone
▾
Store at 20°C to 25°C (68°F to 77°F); excursions are permitted from 15°C to 30°C (59°F to 86°F ) .
Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
Supplements & herbs that interact with Finerenone
146 supplements and herbal products have documented interactions with Finerenone in the licensed clinical database we use. Most are manageable — but your pharmacist should know about everything you take, including vitamins and herbals.
- Major · 3
- Moderate · 101
- Minor · 42
Educational information from a licensed clinical database (Natural Medicines) — see our data sources & update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.
Finerenone: pharmacist answers to common questions
Quick, plain-English answers to the questions patients ask most about Finerenone — the kind of thing our pharmacy team would talk through with you at the counter.
What is Kerendia for?
▾
How do I take it?
▾
Why do I need so many blood tests?
▾
Can I drink grapefruit juice or take my other medicines with it?
▾
What side effects should I expect?
▾
Is it safe in pregnancy or while breastfeeding?
▾
Is Finerenone available over the counter?
▾
When was Finerenone first available?
▾
Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
More about Finerenone on HelloPharmacist
Finerenone forms and strengths (how it comes)
Finerenone is available in 1 form. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Tablet
How this form is used
- Kerendia is used to lower the risk of kidney function decline, end-stage kidney disease, cardiovascular death, non-fatal heart attack and heart failure hospitalization in adults with CKD associated with type 2 diabetes.
- Kerendia is used to lower the risk of cardiovascular death, heart failure hospitalization and urgent heart failure visits in adults with heart failure with LVEF of 40% or higher.
- Kerendia tablets are taken by mouth once daily, with or without food.
- Kerendia can be crushed and mixed with water or soft foods such as applesauce right before use if you can't swallow whole tablets.
- Kerendia missed dose: take it the same day as soon as you notice, otherwise skip it.
- Kerendia needs potassium and eGFR checks before starting and about 4 weeks after starting or changing the dose.
Finerenone on the U.S. market: products, makers and brands
How Finerenone appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
1 company lists 3 Finerenone product records with the FDA, mostly as tablet; the earliest marketing or approval year on record is 2021. Brand names on the directory include Kerendia; the rest are generics.
Also listed with the FDA, not a patient dose form: Powder (8) — bulk drug substance sold to compounders/manufacturers and multi-item kits. These aren’t counted in the dose-form total above.
How widely Finerenone is used (Medicaid data)
A general measure of how commonly Finerenone is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.
Think of this as a proxy for how widely Finerenone is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.
How commonly is Finerenone prescribed? Of the 1,601 medications we measure, Finerenone ranks #542 by Medicaid prescriptions — more than 66% of them.
Utilization by Finerenone product
Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.
finerenone 10 MG Oral Tablet Most dispensed
Summed across the 2 of 6 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2562816
finerenone 20 MG Oral Tablet
Summed across the 2 of 6 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2562824
Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.
Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Finerenone, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 4 of 12 listed Finerenone NDCs with Medicaid activity.
Compare Finerenone products
A representative set of FDA-listed product records for Finerenone — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Tablet | ||||
| 10 mg | Oral | Bayer HealthCare Pharmaceuticals Inc. | NDA | View NDC → |
| 20 mg | Oral | Bayer HealthCare Pharmaceuticals Inc. | NDA | View NDC → |
| 40 mg | Oral | Bayer HealthCare Pharmaceuticals Inc. | NDA | View NDC → |
Showing 3 of 3 products — FDA National Drug Code Directory. See every product, package size and price: browse all 3 Finerenone NDCs →
Finerenone side effects reported to the FDA (FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Finerenone — a signal of what to watch for, not proof the drug caused it.
The effects most often named in FDA reports that mention Finerenone are glomerular filtration rate decreased, hyperkalaemia, blood creatinine increased; about 68% of the reports were classed as serious. These are voluntary reports, so they show what people report, not how often it happens.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Finerenone in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
Finerenone FDA approval history
How Finerenone went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Finerenone was first approved by the FDA in 2021 (Brand: KERENDIA · Bayer Hlthcare). It remains available in U.S. pharmacies today.
Source: Drugs@FDA.
Finerenone recall history
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
The FDA’s enforcement reports list no Finerenone recalls since July 2021.
✅No Finerenone recalls on record since July 2021Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Sep 24, 2026.
RxNorm Concept Web — From Ingredient to Every Form and Strength
This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.
RxCUI 2562811 1 dose form · 3 strengths
-
Dose form (SCDF) Oral Tablet RxCUI 2562815In current FDA listings
Look up RxCUI 2562811 in the RxCUI Atlas →
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
Finerenone supply and shortage status
Whether Finerenone is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
💵 What Finerenone costs pharmacies (NADAC benchmark)
The national average invoice price pharmacies pay for the drug itself, from CMS's NADAC survey (data as of Sep 30, 2026). This is a supply-cost benchmark — not a retail price and not what you'd pay at the counter.
| Form | Strength | Pharmacy acquisition benchmark | |
|---|---|---|---|
| Tablet, Film Coated · Oral | 10 mg | $22.86 per tablet | NDC details & price history |
| Tablet, Film Coated · Oral | 20 mg | $22.85 per tablet | NDC details & price history |
| Tablet · Oral | 40 mg | $22.86 per tablet | NDC details & price history |
| Tablet | 40 mg | $22.86 per tablet | NDC details & price history |
Source: CMS National Average Drug Acquisition Cost (NADAC), a survey of retail pharmacy invoice prices. Benchmarks shown are the range across package sizes of a representative product for each form and strength — other manufacturers' products may differ.
Finerenone brand names
Finerenone is sold under one brand name in the FDA directory — Kerendia. A brand and its generic contain the same active ingredient; the brand name belongs to one company's product.
Who makes Finerenone: manufacturers and labelers
One company lists Finerenone products with the FDA. By number of product records, the largest are Bayer HealthCare Pharmaceuticals Inc.. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.
Finerenone drug class (RxNorm)
Finerenone belongs to the Nonsteroidal Mineralocorticoid-Receptor Antagonist class.
Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.
Sources for this Finerenone page
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How this page is built
HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Bayer Healthcare Pharmaceuticals Inc. is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →